สิทาลิน 50

• SITAGLIPTIN PHOSPHATE62.028 milligramต่อ 1 tablet

ประเภทควบคุม

ยาอันตราย

ข้อบ่งใช้

Monotherapy Sitalin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Combination with metformin Sitalin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with sulfonylurea Sitalin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with PPARɣ agonist Sitalin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a PPARɣ agonist (i.e., thiazolidones) as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with metformin and sulfonylurea Sitalin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control. Combination with metformin and PPARɣ agonist Sitalin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a PPARɣ agonist (i.e., thiazolidones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control. Combination with insulin Sitalin is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin (with or without metformin)

รหัส ATC

A10BH01 (sitagliptin)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ